MAUDE Adverse Event Report: ABBOTT GMBH TOTAL BILIRUBIN; DIAZO COLORIMETRY, BILIRUBIN

Catalog Number	06L45-22
Medical Device Problem Code	High Test Results (2457)
Health Effect - Clinical Code	No Clinical Signs, Symptoms or Conditions (4582)
Date of Event	01/01/2017
Type of Reportable Event	Malfunction
Event or Problem Description
The customer observed falsely elevated architect total bilirubin results generated on the architect c8000 processing module for one patient when compared to other reference labs using a different method.The customer observed the results from the architect are high while the results from the reference labs ((b)(6)) are in the normal range of 0.2-1.2 mg/dl.The customer states the doctor declined to provide results from the reference labs.The customer reviewed the patient results from their facility with results going back to 2017 ranging from 1.3-2.6 mg/dl.Customer states they have no issues with cap failures, calibrations, or quality control issues.An example was provided from 2022 architect (sn (b)(6)) results = 2.3 mg/dl additionally, the following patient total bilirubin results from (b)(6) at the (b)(6) hospital (unknown which are architect or alinity): (b)(6) 2023, sid (b)(6), result = 2.3 mg/dl.(b)(6) 2023, sid (b)(6), result = 1.8 mg/dl.(b)(6) 2023, sid (b)(6), result = 1.9 mg/dl.(b)(6) 2022, sid (b)(6), result = 1.7 mg/dl.(b)(6) 2022, sid (b)(6), result = 1.7 mg/dl.No impact to patient management was reported.
Additional Manufacturer Narrative
Section a1 patient identifier complete information: (b)(6).An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.All available patient information was included.Additional patient details are not available.
Additional Manufacturer Narrative
The complaint investigation for falsely elevated architect total bilirubin results included a review of data and information provided by the customer, search for similar complaints, ticket trending review, labeling review, and device history record review.Data and information provided by the customer were reviewed.Return testing was not completed as returns were not available.Review of tracking and trending for the architect total bilirubin assay did not identify an increase in complaint activity related to the complaint issue, however, a search for similar complaints could not be performed as the complaint lot number is unknown.The device history record review did not identify any potential non-conformances, non-conformances or deviations related to the likely cause list number and complaint issue.Labeling was reviewed and sufficiently addresses the customer's issue.Based on the investigation, no systemic issue or deficiency with the architect total bilirubin assay for unknown lot was identified.All available patient information was included.Additional patient details are not available.
Event or Problem Description
The customer observed falsely elevated arhcitect total bilirubin results generated on the architect c8000 processing module for one patient when compared to other reference labs using a different method.The customer observed the results from the architect are high while the results from the reference labs (sonora quest and mayo clinic roche instrumentation) are in the normal range of 0.2-1.2 mg/dl.The customer states the doctor declined to provide results from the reference labs.The customer reviewed the patient results from their facility with results going back to 2017 ranging from 1.3-2.6 mg/dl.Customer states they have no issues with cap failures, calibrations, or quality control issues.An example was provided from 2022 architect (sn (b)(6) results = 2.3 mg/dl.Additionally, the following patient total bilirubin results from abbott instrumentation at the chandler regional hospital (unknown which are architect or alinity): on (b)(6) 2023, sid (b)(6), result = 2.3 mg/dl.On (b)(6) 2023, sid (b)(6), result = 1.8 mg/dl.On (b)(6) 2023, sid (b)(6), result = 1.9 mg/dl.On (b)(6) 2022, sid (b)(6), result = 1.7 mg/dl.On (b)(6) 2022, sid (b)(6), result = 1.7 mg/dl.No impact to patient management was reported.

• Brand Name: TOTAL BILIRUBIN
• Common Device Name: DIAZO COLORIMETRY, BILIRUBIN
• Manufacturer (Section D): ABBOTT GMBH; max-planck-ring 2; wiesbaden 65205 ; GM 65205
• Manufacturer (Section G): ABBOTT GMBH; max-planck-ring 2; wiesbaden 65205 ; GM 65205
• Manufacturer Contact: nicole jenne ; max-planck-ring 2; post market surveillance; wiesbaden 65205 ; GM 65205 ; 6122582960
• MDR Report Key: 21595441
• Report Number: 3002809144-2025-00082
• Device Sequence Number: 21067652
• Product Code: CIG
• UDI-Device Identifier: 00380740174965
• UDI-Public: (01)00380740174965
• Combination Product (Y/N): N
• Initial Reporter State: AZ
• Initial Reporter Country: US
• PMA/510(K) Number: K121985
• Number of Events Summarized: 1
• Summary Report (Y/N): N
• Serviced by Third Party (Y/N): Unknown
• Reporter Type: Manufacturer
• Report Source: Health Professional
• Initial Reporter Occupation: Other Health Care Professional
• Type of Report: Initial,Followup
• Report Date (Section B): 03/26/2025

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: No
• Is this a Product Problem Report?: Yes
• Operator of Device: Health Professional
• Device Catalogue Number: 06L45-22
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Type of Report(Section G): Initial
• Initial Date Received by Manufacturer: 02/18/2025
• Supplement Date Received by Manufacturer: 03/26/2025
• Initial Report FDA Received Date: 03/13/2025
• Supplement Report FDA Received Date: 03/26/2025
• Was Device Evaluated by Manufacturer? (Y/N): Yes
• Is the Device Labeled for Single Use? (Y/N): No
• Is This a Single-Use Device that was Reprocessed and Reused on a Patient? (Y/N): No
• Patient Sequence Number: 1
• Patient Sex: Unknown